Moнтелукаст Акорд (Montelukast Sodium)

Montelukast sodium selectively blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotrienes D4, E4 and related mediators from triggering bronchoconstriction, mucus production and inflammation in the airways. By inhibiting this pathway, it helps keep the airways open and reduces allergic inflammation.

The appropriate dose of Moнтелукаст Акорд is determined by the prescribing healthcare professional based on the patient’s age, weight, disease severity and other clinical factors. Patients should follow the exact regimen provided by their prescriber and not adjust the dose on their own.

Safety data for montelukast during pregnancy are limited, so it should only be used if the potential benefit justifies any potential risk to the fetus. Montelukast is excreted in breast milk; therefore, nursing mothers should discuss the risks and benefits with their healthcare provider before using the product.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients who have difficulty using inhalers or who need additional control of allergic components of asthma. Its safety profile differs from steroids, with fewer local airway side effects but a distinct set of systemic adverse reactions.

Moнтелукаст Акорд should be stored at room temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, direct sunlight and excessive heat to maintain potency throughout the shelf life.

The medication is taken orally, usually once daily in the evening, with or without food, as directed by the prescriber. Swallow the tablet whole; do not crush, chew, or split it unless specifically instructed by a healthcare professional.

Serious risks, though rare, include severe allergic reactions such as rash, angioedema or anaphylaxis, as well as neuropsychiatric events like depression, mood swings or suicidal thoughts. Hepatic injury and rare skin conditions such as Stevens‑Johnson syndrome have also been reported. Patients should seek immediate medical attention if any of these symptoms appear.

Montelukast should be avoided in individuals with known hypersensitivity to montelukast sodium or any of the tablet’s excipients. Caution is advised for patients with severe liver disease, uncontrolled psychiatric conditions, or those taking medications that may cause significant drug interactions. A healthcare professional should evaluate suitability before initiating therapy.